Citigroup
MNPR icon

Citigroup’s Monopar Therapeutics MNPR Stock Holding History

Citigroup’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$193K Buy
2,088
+1,856
+800% +$115K ﹤0.01% 4362
2026
Q1 		$12.7K Sell
232
-13,608
-98% -$822K ﹤0.01% 4957
2025
Q4 		$904K Buy
13,840
+13,689
+9,066% +$1.12M ﹤0.01% 3203
2025
Q3 		$12.3K Sell
151
-1,292
-90% -$57.8K ﹤0.01% 4955
2025
Q2 		$51.6K Buy
1,443
+1,218
+541% +$44.2K ﹤0.01% 4738
2025
Q1 		$8.19K Buy
+225
New +$8.11K ﹤0.01% 5220

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Citigroup's MNPR Position: Q2 2026 in Review

Citigroup increased its Monopar Therapeutics (MNPR) stake by 800% in Q2 2026, buying an estimated $115K and bringing the position to 2,088 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #4362.

Citigroup first reported a position in MNPR in Q1 2025 and has held it in 6 quarters since. The position peaked at $904K in Q4 2025. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Citigroup held 2,088 shares of Monopar Therapeutics worth $193K as of Q2 2026.
  • Citigroup bought 1,856 Monopar Therapeutics shares in Q2 2026, an estimated $115K.
  • Monopar Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #4362 holding.
  • Citigroup first reported a position in Monopar Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Citigroup's Monopar Therapeutics position peaked at $904K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.